Original ArticlesMultitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer
Key Words
Cited by (0)
This study was supported, in part, by grants from the National Cancer Institute to the North Central Cancer Treatment Group (CA25224) and to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, MD, Chair, CA31946) and to the Alliance Statistics and Data Center (Daniel J. Sargent, PhD, CA33601). NCIC Clinical Trials Group is supported by funding received from the Canadian Cancer Society Research Institute (Grants #021039 and #015469) and the JCOG trial was supported by the Grant of Ministry of Health, Labour and Welfare in Japan. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute, the National Institute of Health, or the other groups (JCOG, Canadian Cancer Society Research Institute).
Disclosure: Nathan R. Foster, MS, Lindsay A. Renfro PhD, Sumithra J. Mandrekar, PhD, and Keyue Ding, PhD received NCI or NIH grant support for the submitted work, Xiaofei F. Wang, PhD received Duke University and NIH funding for the submitted work, Suresh S. Ramalingam, MD received consultancy money from the following companies: Abbrie, Amgen, Celgene, AstraZeneca, Ariad, Areo, Lilly, Genentech, Novartis, and BMS. For the remaining authors, none were declared.